혈당 측정기 시장 : 제품별, 용도별, 유통 채널별 - 세계 예측(2024-2032년)

Global Glucometer Market size will witness 12.8% CAGR between 2024 and 2032 propelled by the ongoing R&D activities in the field of diabetes management. As researchers develop innovative technologies and improve the accuracy and efficiency of glucometers, healthcare providers and individuals with diabetes are seeking advanced solutions. For instance, in March 2024, researchers at IIT Mandi introduced a groundbreaking device capable of detecting diabetes without the necessity of blood samples. Termed as a non-invasive glucometer, this device functions by analyzing breath samples contained in a balloon for providing a painless and effective alternative to conventional methods.

With a growing emphasis on personalized healthcare and proactive disease management, the demand for glucometers with advanced capabilities will continue to rise for shaping the landscape of diabetes care. Rising efforts towards enhanced features, such as continuous glucose monitoring, wireless connectivity, and smartphone integration will also drive the market growth.

The overall glucometer industry is classified into product type, application, distribution channel and region.

In terms of product type, the market share from the self-monitoring blood glucose meters segment will undergo significant development, depicting 15% CAGR from 2024 to 2032. These devices empower individuals with diabetes to monitor their blood glucose levels conveniently and accurately at home or on the go. With the increasing prevalence of diabetes worldwide, there is a growing need for effective self-management tools. Self-monitoring blood glucose meters offer users real-time insights into their glucose levels for facilitating proactive management of their condition. With individuals prioritizing proactive health monitoring, the demand for self-monitoring blood glucose meters will continue to grow steadily.

Based on application, the glucometer industry revenue from the type 1 diabetes segment will register a 12.4% CAGR from 2024 to 2032. As type 1 diabetes requires regular monitoring of blood glucose levels to manage insulin dosages effectively, glucometers play a crucial role in daily management routines. These devices provide users with real-time feedback on their glucose levels, enabling timely interventions to maintain optimal health. With the rising prevalence of type 1 diabetes globally, the demand for accurate and reliable glucometers tailored to the needs of individuals with this condition will further increase.

Asia pacific glucometer market will showcase a 13.5% CAGR from 2024 to 2032. With a growing prevalence of diabetes and an increasing focus on proactive healthcare management, there is a heightened demand for glucometers in the region to enable individuals to monitor their blood glucose levels conveniently and effectively for disease management. The improving healthcare infrastructure and awareness is further driving the demand for glucometers tailored to the diverse needs of the Asia Pacific population. For instance, in October 2023, the state governments of Mumbai (India) decision to permit students in Class 1-12 with Type-1 diabetes to consume snacks and medication and a glucometer in classrooms and examination halls was warmly received by schools, parents, and NGOs.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of diabetes worldwide
    • 3.2.1.2 Technological advancements
    • 3.2.1.3 Rising demand for self-monitoring devices globally
    • 3.2.1.4 Government initiatives for increasing awareness among people
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of advanced devices and accessories
    • 3.2.2.2 Lack of reimbursement and stringent regulations
• 3.3 Growth potential analysis
• 3.4 Technology landscape
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutes
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategic outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Self-monitoring blood glucose meters
• 5.3 Continuous glucose monitors
  • 5.3.1 Wearable
  • 5.3.2 Non - wearable

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Type 1 diabetes
• 6.3 Type 2 diabetes
• 6.4 Gestational diabetes

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 Online sales
• 7.5 Diabetes clinics & centers

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Poland
  • 8.3.7 Switzerland
  • 8.3.8 Sweden
  • 8.3.9 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Indonesia
  • 8.4.7 Thailand
  • 8.4.8 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Colombia
  • 8.5.5 Chile
  • 8.5.6 Peru
  • 8.5.7 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 Kuwait
  • 8.6.4 UAE
  • 8.6.5 Turkey
  • 8.6.6 Egypt
  • 8.6.7 Israel
  • 8.6.8 Qatar
  • 8.6.9 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 AgaMatrix
• 9.3 All Medicus Co., Ltd.
• 9.4 Ascensia Diabetes Care Holdings AG
• 9.5 Arkray, Inc.
• 9.6 B. Braun Melsungen AG
• 9.7 Bionime Corporation
• 9.8 DarioHealth Corporation
• 9.9 Dexcom, Inc.
• 9.10 Essenlife Bioscience, Inc.
• 9.11 F. Hoffmann-La Roche Ltd.
• 9.12 LifeScan Inc.
• 9.13 Medtronic plc
• 9.14 Nova Biomedical, Inc.
• 9.15 Sinocare Inc.